https://www.newsfilecorp.com/release/47148
CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program
Anyone catch the end
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/
Phoenix, Arizona--(Newsfile Corp. - August 22, 2019) - The Stock Day Podcast welcomed CytoDyn (OTCQB: CYDY) ("the Company"
, a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the progress of the Company's current HIV program. Dr. Pourhassan explained that CytoDyn's HIV program consists of three branches. The first branch involves the use of leronlimab in combination with standard anti-retroviral therapies for unmet medical HIV population. This division of the Company has already completed Phase 3 trials and could potentially gain final approval in the near future, which would allow for its release by the second quarter of next year. Second branch of CytoDyn's HIV program involves the use of leronlimab as a once-weekly monotherapy program for HIV-infected patients, which has also completed one investigative Phase 3 clinical trial and is meeting with the FDA to finalize a final trial for approval as label expansion.
Jolly then asked about the potential of the HIV market. Dr. Pourhassan explained that this market is currently valued around $10 billion. Dr. Pourhassan then explained that the Company is close to the final approval of their HIV program and already has close to $60 million worth of commercial product ready for launch. "When we get approval, we have assets that we will be able to use," stated Dr. Pourhassan.
Dr. Pourhassan then expanded on the Company's third branch of their HIV program, lead by Dr. Jonas Sacha. This aspect of the Company was designed to explore the potential of leronlimab (PRO 140) in HIV Pre-Exposure Prophylaxis (PrEP) and cure, and has had great success. Dr. Pourhassan shared that new results from Dr. Jonas Sacha will be released later this year and he believes it will have a significant impact on the HIV industry. CytoDyn has already signed an Memorandum of Understanding with Thai Red Cross for a PrEP study funded outside of CytoDyn.
Dr. Pourhassan then expanded on the Company's plans to fund the launch of their HIV program. He shared that the Company has been offered one substantial opportunity and working on a second one also, which will include significant upfront and milestone payments. "We're eager to get one of those deals signed and let our shareholders know that we're really entering the revenue era soon", said Dr. Pourhassan.
Jolly then asked about the Company's non-HIV programs. Dr. Pourhassan explained that the Company is currently entering Phase 2 trials for the use of leronlimab in treating metastatic triple-negative breast cancer. He shared that animal studies were extremely successful, which if replicated in humans then it could represent massive value in the treatment of cancer. The Company is also adapting their program to help with the treatment of fibrosis, as well as colon cancer.
Jolly asked about the Company's plans for potential partnerships or licensing. Dr. Pourhassan shared that the Company is very close to signing a licensing agreement, which represents an important step towards the production of their HIV program.
To close the interview, Jolly noted that the Company is exceptionally undervalued and represents a great opportunity for investors interested in this space.
CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program
Anyone catch the end
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/
Phoenix, Arizona--(Newsfile Corp. - August 22, 2019) - The Stock Day Podcast welcomed CytoDyn (OTCQB: CYDY) ("the Company"
, a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the progress of the Company's current HIV program. Dr. Pourhassan explained that CytoDyn's HIV program consists of three branches. The first branch involves the use of leronlimab in combination with standard anti-retroviral therapies for unmet medical HIV population. This division of the Company has already completed Phase 3 trials and could potentially gain final approval in the near future, which would allow for its release by the second quarter of next year. Second branch of CytoDyn's HIV program involves the use of leronlimab as a once-weekly monotherapy program for HIV-infected patients, which has also completed one investigative Phase 3 clinical trial and is meeting with the FDA to finalize a final trial for approval as label expansion.
Jolly then asked about the potential of the HIV market. Dr. Pourhassan explained that this market is currently valued around $10 billion. Dr. Pourhassan then explained that the Company is close to the final approval of their HIV program and already has close to $60 million worth of commercial product ready for launch. "When we get approval, we have assets that we will be able to use," stated Dr. Pourhassan.
Dr. Pourhassan then expanded on the Company's third branch of their HIV program, lead by Dr. Jonas Sacha. This aspect of the Company was designed to explore the potential of leronlimab (PRO 140) in HIV Pre-Exposure Prophylaxis (PrEP) and cure, and has had great success. Dr. Pourhassan shared that new results from Dr. Jonas Sacha will be released later this year and he believes it will have a significant impact on the HIV industry. CytoDyn has already signed an Memorandum of Understanding with Thai Red Cross for a PrEP study funded outside of CytoDyn.
Dr. Pourhassan then expanded on the Company's plans to fund the launch of their HIV program. He shared that the Company has been offered one substantial opportunity and working on a second one also, which will include significant upfront and milestone payments. "We're eager to get one of those deals signed and let our shareholders know that we're really entering the revenue era soon", said Dr. Pourhassan.
Jolly then asked about the Company's non-HIV programs. Dr. Pourhassan explained that the Company is currently entering Phase 2 trials for the use of leronlimab in treating metastatic triple-negative breast cancer. He shared that animal studies were extremely successful, which if replicated in humans then it could represent massive value in the treatment of cancer. The Company is also adapting their program to help with the treatment of fibrosis, as well as colon cancer.
Jolly asked about the Company's plans for potential partnerships or licensing. Dr. Pourhassan shared that the Company is very close to signing a licensing agreement, which represents an important step towards the production of their HIV program.
To close the interview, Jolly noted that the Company is exceptionally undervalued and represents a great opportunity for investors interested in this space.
3
